Am J Clin Oncol 2000 Jun;23(3):319-21
Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide
Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D.Anderson Cancer Center, Houston, USA.
Thalidomide, a sedative agent previously associated with severe fetal malformations, has anti-angiogenic activity. We describe the antitumor effects of thalidomide in a patient with hepatocellular carcinoma that was refractory to systemic and intraarterial therapy.
Chi siamo Faq Links Reviews News E-mail Casi clinici